1
|
Liu C, Xu P, Shao S, Wang F, Zheng Z, Li S, Liu W, Li G. The value of urinary exosomal lncRNA SNHG16 as a diagnostic biomarker for bladder cancer. Mol Biol Rep 2023; 50:8297-8304. [PMID: 37592177 PMCID: PMC10520200 DOI: 10.1007/s11033-023-08667-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Accepted: 07/06/2023] [Indexed: 08/19/2023]
Abstract
OBJECTIVE To detect the expression level of urinary exosomal lncRNA SNHG16 in patients with bladder cancer and healthy individuals and explore its clinical application value in the diagnosis of bladder cancer. METHODS Urine samples were collected from 42 patients with bladder cancer and 42 healthy volunteers who visited Lu'an Hospital of Anhui Medical University and the Second Hospital of Tianjin Medical University from January 2020 to December 2022. The expression levels of lncRNA SNHG16 in urinary exosomes of the two groups were detected by RT‒qPCR, and their correlation with clinical pathological parameters of bladder cancer patients was analysed. An Receiver Operating Characteristic(ROC) curve was drawn to analyse the diagnostic value of urinary exosomal lncRNA SNHG16 for bladder cancer and compared with urinary cytology. RESULTS The expression of urinary exosomal lncRNA SNHG16 in patients with bladder cancer was significantly higher (P < 0.05), and the expression level had no correlation with the age, sex, pathological T stage, pathological grade, or tumour size of bladder cancer patients (P > 0.05). The Area Under Curve(AUC) of urinary exosomal lncRNA SNHG16 in diagnosing bladder cancer was 0.791, which was superior to that of urinary cytology (AUC = 0.597). CONCLUSION Urinary exosomal lncRNA SNHG16 with high expression can serve as a potential diagnostic biological marker for bladder cancer.
Collapse
Affiliation(s)
- Chengyi Liu
- Department of Urology, Lu'an People's Hospital of Anhui Province, Lu'an Hospital of Anhui Medical University, No.21, Wanxi West Road, Lu'an, 237000, Anhui, China
| | - Pengcheng Xu
- Department of Urology, Lu'an People's Hospital of Anhui Province, Lu'an Hospital of Anhui Medical University, No.21, Wanxi West Road, Lu'an, 237000, Anhui, China
| | - Song Shao
- Department of Orthopaedic, Lu'an People's Hospital of Anhui Province, Lu'an Hospital of Anhui Medical University, Lu'an, 237000, China
| | - Fang Wang
- Department of Pharmacy, Lu'an People's Hospital of Anhui Province, Lu'an Hospital of Anhui Medical University, Lu'an, 237000, China
| | - Zhiwen Zheng
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China
| | - Shuangjie Li
- Department of Urology, Lu'an People's Hospital of Anhui Province, Lu'an Hospital of Anhui Medical University, No.21, Wanxi West Road, Lu'an, 237000, Anhui, China
| | - Wei Liu
- Department of Urology, Lu'an People's Hospital of Anhui Province, Lu'an Hospital of Anhui Medical University, No.21, Wanxi West Road, Lu'an, 237000, Anhui, China
| | - Guangyuan Li
- Department of Urology, Lu'an People's Hospital of Anhui Province, Lu'an Hospital of Anhui Medical University, No.21, Wanxi West Road, Lu'an, 237000, Anhui, China.
- The First Affiliated Hospital of Anhui Medical University, Anhui Public Health Clinical Center, An Hui Sheng, China.
| |
Collapse
|
2
|
Seles M, Mischinger J, Zigeuner R. Conservative Treatment of Upper Urinary Tract Urothelial Carcinoma: Con. EUR UROL SUPPL 2021; 32:35-37. [PMID: 34522903 PMCID: PMC8429919 DOI: 10.1016/j.euros.2021.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/05/2021] [Indexed: 12/02/2022] Open
Affiliation(s)
- Maximilian Seles
- Department of Urology, Medical University of Graz, Graz, Austria
| | | | - Richard Zigeuner
- Department of Urology, Medical University of Graz, Graz, Austria
| |
Collapse
|
3
|
Zhang B, Li J, Wu Z, Li C, Sun T, Zhuo N, Liang J, Duan Q, Hu H, Tian J. Contrast-Enhanced Ultrasound Characteristics of Renal Pelvis Urothelial Carcinoma and Its Relationship with Microvessel Density. ULTRASOUND IN MEDICINE & BIOLOGY 2021; 47:236-243. [PMID: 33158635 DOI: 10.1016/j.ultrasmedbio.2020.09.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2020] [Revised: 07/23/2020] [Accepted: 09/11/2020] [Indexed: 06/11/2023]
Abstract
We studied the characteristics of contrast-enhanced ultrasound (CEUS) in renal pelvic urothelial carcinomas and explored its performance in assessing microvessel density (MVD) of tumor tissues. We retrospectively analyzed the characteristics of 125 cases, which were confirmed pathologically to be renal pelvic urothelial carcinomas using CEUS. We performed CEUS and found that most tumors presented with an enhanced mode of "slow-in (mean = 16.7 ± 2.6 s, range: 12-25 s), hypo-enhancement and fast-out (mean = 69.3 ± 16.2 s, range: 42-113 s)." However, the wash-in pattern, homogeneity and wash-out pattern observed with CEUS was not correlated with pT stage and grade (p > 0.05). But advanced-pT-stage and high-grade tumors had a higher peak enhancement than early-pT-stage and low-grade tumors (p < 0.01). Peak enhancement obtained with CEUS can be used to evaluate the pT stage and grade of renal pelvic urothelial carcinomas more effectively. The MVD of those tissues was observed using immunohistochemical staining of cluster of differentiation 34 (CD34). MVD in the advanced-pT-stage and high-grade groups was significantly higher than that in the early-pT-stage and low-grade groups (p < 0.01). As tumor pT stage and grade improved, CEUS peak enhancement intensity and MVD of tumors also exhibited an upward trend. CEUS peak enhancement intensity has the potential to determine MVD of renal pelvic urothelial carcinomas.
Collapse
Affiliation(s)
- Bo Zhang
- Department of Ultrasound, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Jing Li
- Department of Ultrasound, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Zhouliang Wu
- Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Chenyun Li
- Department of Ultrasound, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Tong Sun
- Department of Ultrasound, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Na Zhuo
- Department of Ultrasound, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Jixiang Liang
- Department of Ultrasound, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Qing Duan
- Department of Ultrasound, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Hailong Hu
- Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China
| | - Jing Tian
- Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China.
| |
Collapse
|
4
|
Omorphos NP, Piedad JCP, Vasdev N. Guideline of guidelines: Muscle-invasive bladder cancer. Turk J Urol 2020; 47:S71-S78. [PMID: 32966207 DOI: 10.5152/tud.2020.20337] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Accepted: 08/10/2020] [Indexed: 11/22/2022]
Abstract
Muscle-invasive bladder cancer accounts for 25% of bladder cancer cases and represents a spectrum of disease, which can result in significant morbidity and mortality for anyone affected. Current management has evolved through years of research and clinical practice. It is based on a risk-benefit approach, which is often tailored to the individual requirements of patients and involves cystectomy, neoadjuvant and adjuvant therapies, and multimodal surveillance paradigms to achieve high survival rates. Multiple guidelines exist to assist the clinicians in this decision-making process, but their adherence is often variable. In this article, we aimed to review the 4 most commonly used guidelines from the European Association of Urology, the National Institute for Health and Care Excellence, the National Comprehensive Cancer Network, and the American Urological Association.
Collapse
Affiliation(s)
- Nicolas Pavlos Omorphos
- Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK
| | - John Carlo Pansaon Piedad
- Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK
| | - Nikhil Vasdev
- Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.,School of Medicine and Life Sciences, University of Hertfordshire, Hatfield, UK
| |
Collapse
|
5
|
Abstract
Follow-up care of patients with muscle-invasive bladder cancer is subdivided into oncological and functional surveillance. More than 80% of local relapses and distant metastases occur within the first 2 years. Recurrences in the remnant urothelium also occur several years after radical cystectomy. Urinary cytology and a computed tomography (CT) scan of the abdomen and thorax including a urography phase are the standard diagnostics for tumor follow-up. There is no clear evidence for a survival benefit for the detection of asymptomatic vs. symptomatic recurrences. After partial cystectomy or trimodal treatment, there is no established follow-up schedule; however, the relatively high incidence of intravesical recurrences should be considered as there are curative treatment approaches including salvage cystectomy. Functional surveillance, which should be carried out lifelong, encompasses prevention and diagnostics of metabolic complications, urethral/ureteral strictures, problems with the urinary stoma, urinary incontinence, sexual dysfunction and urinary tract infections.
Collapse
|
6
|
[Aftercare of non-muscle invasive bladder cancer]. Urologe A 2019; 58:943-952. [PMID: 31175377 DOI: 10.1007/s00120-019-0956-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Tumor follow-up in patients with non-muscle invasive bladder cancer (NMIBC) is a weighing up between the morbidity associated with invasive diagnostics and the risk of tumor recurrence and especially progression. The risk stratification into low, intermediate, and high-risk tumors enables a risk-adapted follow-up. For individual estimation of the risk of progression and recurrence, risk calculators should be used. Follow-up is still based on cystoscopy, which is recommended lifelong for high and intermediate-risk tumors and for up to 5 tumor-free years for low-risk tumors. Urine cytology has a high sensitivity and specificity for high-risk tumors and is recommended in the follow-up care. There is currently no recommendation for any commercially available urinary marker due to inadequate evidence. For the clarification of synchronous and metachronous tumors of the upper urinary tract computed tomography (CT) urography or alternatively magnetic resonance (MR) urography is recommended.
Collapse
|